Summary
In the present study, an attempt was made to clarify whether ANP molecular forms in the plasma of severe congestive heart failure patients differ from those in healthy persons and whether ANP molecular forms in the plasma of the patients were changed by successful treatment of cardiac disease.
Twenty patients with congestive heart failure were treated at Kitasato University Hospital. They were classified as class III or IV by New York Heart Association criteria at the time of admission. Plasma ANP concentrations decreased after treatment from 356 ± 58.2 to 72.3 ± 14.8 pg/ml. The gel permeation chromatograms from the plasma of healthy persons showed low, or low and high molecular weight ANP peaks which correspond to the elution positions of authentic α-ANP or ribonuclease A (mol.wt., 13.7 kdalton). In patients with severe congestive heart failure at a severe stage, middle molecular weight ANP consisted with the elution position of authenticβ-ANP was particularly noted in addition of low and high molecular weight ANP peaks. This middle molecular weight peak disappears in most of cases by successful treatment. Molecular forms in the plasma obtained from the coronary sinus and the inferior or superior vena cava were essentially the same.
These results indicate that the middle molecular weight ANP supposed asβ-ANP may particularly be secreted in severe congestive heart failure patients.
Similar content being viewed by others
Abbreviations
- ANP:
-
atrial natriuretic peptide
- NYHA criteria:
-
New York Heart Association criteria
- SIADH:
-
Syndrome of inappropriate secretion of ADH
References
Arendt RM, Gerbes AL, Ritter D, Stnagl E (1986) Molecular weight heterogeneity of plasma-ANF in cardiovascular disease. Klin Wochenschr 64: (Suppl VI):97–102
Eisenhauer T, Talartschik J, Scheler F (1986) Detection of fluid overload by plasma concentration of human atrial natriuretic peptide (h-ANP) in patients with renal failure. Klin Wochenschr 64:68–72
Kangawa K, Matsuo H (1984) Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Comm 118:131–139
Katoh Y, Kurosawa T, Takeda S, Sakamoto H, Marumo F, Kikawada R (1986) Atrial natriuretic peptide levels in treated congestive heart failure. Lancet I:851
Kurokawa S, Katoh Y, Sugiyama T, Kurosawa T, Takeda S, Sakamoto H, Marumo F, Kikawada R (1987) Correlation of decreased plasma atrial natriuretic peptide level with left atrial diameter in chronic hemodialysis. Am J Cardiol 60:1135
Marumo F, Sakamoto H, Ando K, Ishigami T, Kawakami M (1986) A highly sensitive radioimmunoassay of atrial natriuretic peptide (ANP) in human plasma and urine. Biochem Biophys Res Comm 137:231–236
Misono KS, Fukumi H, Grammer RT, Inagami T (1984) Rat atrial natriuretic factor: Complete amino acid sequence and disulfide linkage essential for biological activity. Biochem Biophys Res Comm 119:524–529
Miyata A, Toshimori T, Hashiguchi T, Kangawa K, Matsuo H (1987) Molecular forms of atrial natriuretic polypeptides circulating in human plasma. Biochem Biophys Res Comm 142:461–467
Nakaoka H, Imataka K, Amano J, Ishibashi M, Yamaji T (1985) Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med 313:892–893
Petzl DH, Hartter E, Osterode W, Böhm H, Woloszcuk W, Schuster E (1986) Plasma atrial natriuretic peptide concentrations in the recovery period of myocardial infarction in arterial and venous blood samples. Horm Metabol Res 18:501–502
Sagnella G, Markandu ND, Shore AC, MacGregor GA (1986) Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet I:179–181
Sakamoto H, Inoue K, Marumo F (1986) High plasma atrial natriuretic peptide independent of sodium balance in SIADH. JAMA 256:1293–1294
Sugawara A, Nakao K, Morii N, Yamada T, Itoh H, Shiono S, Saito Y, Mukoyama M, Arai H, Nishimura K, Obata K, Yasue H, Ban T, Imura H (1988) Augmented synthesis of α-human atrial natriuretic polypeptide in human failing hearts. Biochem Biophys Res Comm 150:60–67
Yamada K, Tajima K, Moriwaki K, Tarui S, Kangawa K, Matsuo H (1986) Atrial natriuretic peptide in Bartter's syndrome. Lancet I:273
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marumo, F., Kurosawa, T., Takeda, S. et al. Changes of molecular forms of atrial natriuretic peptide after treatment for congestive heart failure. Klin Wochenschr 66, 675–681 (1988). https://doi.org/10.1007/BF01726925
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01726925